This message contains images. If you don't see images, click here to view.
Advertise in this news brief.


Text version   RSS   Subscribe   Unsubscribe   Archive   Media Kit September 21, 2016    SLAS2017    Moving? New job? Let SLAS know.      


Travel Awards Enable SLAS2017 Participation

Students, graduate students, post-doctoral associates and junior faculty may apply for travel awards. 60 awarded for SLAS2016.



Sept. 26 Deadline for SLAS2017 Tony B. Academic Travel Award Applications
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
There's still time to submit a scientific poster abstract and earn the chance to attend SLAS2017. Tony B. Awards are for up-and-coming researchers who have outstanding achievements to share. If selected for an Award, the primary poster author earns travel, hotel accommodations and a full conference registration for SLAS2017, Feb. 4-8, Washington, DC.

Read more about the man behind the award.


Sept. 23 SLAS Webinar: Compound Screening and Profiling in Cultured Human (3D) Tissues
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The examination of tissue morphology by histopathologists is invaluable in the diagnosis of disease, and the morphology of 3D cultured tissues can provide rich insight into the diseased state and the impact of drug treatment — both therapeutic and adverse.

Learn how to exploit the phenotypic complexity of 3D tissues in this live SLAS Webinar on Friday, Sept. 23 at 10 a.m. EDT, with Leo Price, CEO of OcellO. Dues-paying SLAS members may participate — live or on demand — at no cost. SLAS Webinars are presented by the official scientific journals of SLAS.

Sponsored Content

Sept. 30 Deadline: JBS Special Issue Call for Papers on Advances in MALDI Mass Spectrometry for Drug Discovery
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Are you working with high-throughput MALDI applications, MALDI in enzyme characterization or MALDI imaging for metabolite detection and screening and for drug distribution studies? These are a few of the interest areas sought by JBS guest editors Shannon Cornett, Ph.D., of Bruker and Michael Scholle, M.S., M.B.A. of SAMDI Tech.

Submit your manuscript proposals (abstracts) by Sept. 30 for this 2017 special issue of SLAS Discovery. Proposals will be used to select papers for submission and peer review.

Welcome to RAD Source
Since 1997 Rad Source Technologies has been the expert in providing renewable, non-isotope, ionizing radiation replacements for self-shielded gamma irradiators. Currently, there are over 300 renowned hospital, university, and pharmaceutical research institutions using Rad Source X-ray technology. To find out more about our equipment, select your application and you will find equipment specifications, literature references, white papers, training videos, discussion forums, as well as other helpful info.

SLAS Nominations Committee Now Accepting Applications for SLAS Board of Directors
SLAS     Share    Share on FacebookTwitterShare on LinkedinE-mail article
The SLAS Nominations Committee will soon select three individuals to join the SLAS Board of Directors for three-year terms of service beginning in 2017. Candidate applications for the SLAS Board of Directors are being accepted from the membership community through Oct. 5.

All candidates must have the capacity and commitment to serve, and meet the required criteria outlined in the SLAS Strategic Plan, SLAS Board of Directors Selection Policy and the SLAS Bylaws. The new board members will replace those completing their board terms: Alastair Binnie, Richard Eglen and Mike Snowden.


JBS Open Access: Development of a 3D Tissue Culture-Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
NEW and FREE at JBS Online is this collaborative work from a Leiden University, OcellO and Semmelweis University team. The team concludes, "Combining the advantages of physiological relevance and phenotypic complexity, phenotypic screening and profiling with 3D cell cultures has the potential to improve the quality of hits from screens and make previously challenging targets more accessible, potentially leading to a higher success rate of molecules in clinical trials."

This is a SAGE Choice article, allowing all readers immediate free access to the full manuscript. Contributing author Leo Price, Ph.D., presents an SLAS Webinar, "Compound Screening and Profiling in Cultured Human (3D) Tissues," on Sept. 23.

Accelerate your NGS Success

Fast, accurate sequencing begins with automated NGS Sample Prep from Agilent.

SLAS2017 Short Course Spotlight: 3D Cell-Based Assays for Drug De-Risking
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
3D cell culture technologies, assays and their use in drug discovery and development are topics covered in this full-day SLAS2017 Short Course, Saturday, Feb. 4. Instructors Helena Hogberg, deputy director of the Center for Alternatives to Animal Testing at John Hopkins Bloomberg School of Public Health and Jens M. Kelm, chief scientific officer and co-founder of InSphero expect industry and academic scientists with mid- to advanced-level experience in cell-based assays or cell biology wishing to get a concise overview about technologies, advantages, cost and application examples of 3D cell-based assays will benefit most from attendance.

"3C Cell-Based Assays for Drug De-Risking" is one of 21 half-, one- and two-day courses to be held at SLAS2017.

Sponsored Content

Share the SLAS Story
SLAS    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Do you have colleagues who could benefit from the opportunities offered by SLAS membership?

Tell them why you belong and share this link so they can learn first-hand how others have advanced their careers and enhanced their personal lives through SLAS membership.


Covalent Drugs Target Cancer Protein via New Linker
Chemical & Engineering News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In healthy cells, the protein Mcl-1 does its job by interfacing with other proteins and blocking them from triggering apoptosis, or programmed cell death. In some types of cancer cells, though, there's an overabundance of Mcl-1, which protects the malignant cells and enables rampant tumor growth. Researchers from AstraZeneca have now successfully "drugged" Mcl-1 by creating what they say are the first reversible covalent inhibitors of a protein-protein interaction. More

Genomic Signatures Clearly Dictate Schizophrenic Drug Responses
Genetic Engineering & Biotechnology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A drug prescribed to many patients with schizophrenia or bipolar disorder may decrease negative symptoms for people with a certain variant of the COMT gene, according to scientists from Columbia University Medical Center. The mood stabilizer valproate is commonly prescribed to treat bipolar disorder and schizophrenia, though its mechanism of action is poorly understood and only some patients respond to the treatment. More

Catalytic Proton Dynamics at the Water/Solid Interface of Ceria-Supported Pt Clusters
Journal of the American Chemical Society    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Wet conditions in heterogeneous catalysis can substantially improve the rate of surface reactions by assisting the diffusion of reaction intermediates between surface reaction sites. The atomistic mechanisms underpinning this accelerated mass transfer are, however, concealed by the complexity of the dynamic water/solid interface. Here we employ ab initio molecular dynamics simulations to disclose the fast diffusion of protons and hydroxide species along the interface between water and ceria, a catalytically important, highly reducible oxide. More

Gene Therapy Technique May Help Prevent Cancer Metastasis
Bioscience Technology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The spread of malignant cells around the body, known as metastasis, is the leading cause of mortality in women with breast cancer. Now, a new gene therapy technique being developed by researchers at MIT is showing promise as a way to prevent breast cancer tumors from metastasizing. The treatment, described in a paper published in the journal Nature Communications, uses microRNAs — small noncoding RNA molecules that regulate gene expression — to control metastasis. More

Large-Scale Metabolite Analysis of Standards and Human Serum by Laser Desorption Ionization Mass Spectrometry from Silicon Nanopost Arrays
Analytical Chemistry    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The unique challenges presented by metabolomics have driven the development of new mass spectrometry (MS)-based techniques for small molecule analysis. We have previously demonstrated silicon nanopost arrays (NAPA) to be an effective substrate for laser desorption ionization (LDI) of small molecules for MS. However, the utility of NAPA-LDI-MS for a wide range of metabolite classes has not been investigated. More

Researchers Discover More Efficient Way to Split Water, Produce Hydrogen    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Hydrogen is often considered a fuel for the future, in the form of fuel cells to power electric motors or burned in internal combustion engines. But finding a practical, inexpensive and nontoxic way to produce large amounts of hydrogen gas — especially by splitting water into its component parts, hydrogen and oxygen — has been a challenge. A team of researchers has reported a more efficient catalyst, using molybdenum sulfoselenide particles on three-dimensional porous nickel diselenide foam to increase catalytic activity. More

Drug-Loaded Synthetic Nanoparticles Can Distinguish Lung Cancer Cells From Healthy Cells
Science Daily    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Researchers with the Harold C. Simmons Comprehensive Cancer Center successfully developed a synthetic polymer that can transport a drug into lung cancer cells without going inside of normal lung cells. Since conventional chemo drugs indiscriminately kill all rapidly dividing cells to halt the growth of cancer, these selective nanoparticles could decrease side effects by reducing drug accumulation in normal cells. More

UCLA Chemistry Professor Makes Strides in Improving Laboratory Safety Nationally
Lab Manager    Share    Share on FacebookTwitterShare on LinkedinE-mail article
As a chemistry graduate student at the University of Wisconsin, Madison in the 1980s, Craig Merlic saw numerous accidents in his research group's laboratory. "We had fires, explosions, people who had chemicals spilled on them," he recalled. "That had a lasting impact on me and my activities at UCLA." Merlic, an associate professor of chemistry at UCLA who conducts research in organic chemistry and green chemistry, has been committed to laboratory safety for three decades — and not just in his laboratory. More


Quality Engineer – Reagents
Pacific Biosciences
US – CA – Menlo Park

Postdoctoral Associate in Translational Immunobiology
Duke University School of Medicine
US – NC – Durham

Microbiologist – Technical Leadership Program
Sealed Air
US – NC – Charlotte

Search Jobs at SLAS Career Connections


SLAS Point-to-Point
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Dennis Hall, Executive Editor, 469.420.2656   
Contribute news

This edition of SLAS Point-to-Point was sent to ##Email##. To unsubscribe from receiving SLAS Point-to-Point, click here. To unsubscribe from all SLAS e-mail communications, please click here. Did someone forward this edition to you? Subscribe here — it's free!

SLAS Terms of Use Policy
Recent issues

Sept. 14, 2016
Sept. 7, 2016
Aug. 31, 2016
Aug. 24, 2016

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063